Search

Your search keyword '"Pasi Pohjanjousi"' showing total 3 results
Start Over Author "Pasi Pohjanjousi" Search Limiters Peer Reviewed
3 results on '"Pasi Pohjanjousi"'

1. Survivorship Data in Prostate Cancer: Where Are We and Where Do We Need To Be?

Author

Beth Russell, Katharina Beyer, Ailbhe Lawlor, Monique J. Roobol, Lionne D.F. Venderbos, Sebastiaan Remmers, Erik Briers, Sara J. MacLennan, Steven MacLennan, Muhammad Imran Omar, Mieke Van Hemelrijck, Emma Smith, James N'Dow, Karin Plass, Maria Ribal, Nicolas Mottet, Robert Shepherd, Tom Abbott, Ken Mastris, Lisa Moris, Michael Lardas, Thomas Van den Broeck, Peter-Paul Willemse, Nicola Fossati, Karl Pang, Riccardo Campi, Isabella Greco, Mauro Gacci, Sergio Serni, Anders Bjartell, Ragnar Lonnerbro, Alberto Briganti, Daniele Crosti, Roberto Garzonio, Giorgio Gandaglia, Martina Faticoni, Grant office, Chris Bangma, Maria Jongerden, Derya Tilki, Anssi Auvinen, Teemu Murtola, Tapio Visakorpi, Kirsi Talala, Teuvo Tammela, Aino Siltari, Stephane Lejeune, Laurence Colette, Simona Caputova, Delielena Poli, Sophie Byrne, Luz Fialho, Ashley Rowland, Neo Tapela, Nicola Di Flora, Kathi Apostolidis, Valerie Lemair, Bertrand De Meulder, Charles Auffray, Nesrine Taibi, Ayman Hijazy, Albert Saporta, Kai Sun, Shaun Power, Nazanin Zounemat Kermani, Kees van Bochove, Azadeh Tafreshiha, Chiara Bernini, Denis Horgan, Louise Fullwood, Marc Holtorf, Doron Lancet, Gabi Bernstein, Sheela Tripathee, Manfred Wirth, Michael Froehner, Beate Brenner, Angelika Borkowetz, Christian Thomas, Friedemann Horn, Kristin Reiche, Markus Kreuz, Andreas Josefsson, Delila Gasi Tandefelt, Jonas Hugosson, Jack Schalken, Henkjan Huisman, Thomas Hofmarcher, Peter Lindgren, Emelie Andersson, Adam Fridhammar, Monica Tames Grijalva, Susan Evans-Axelsson, Frank Verholen, Jihong Zong, John-Edward Butler-Ransohoff, Todd Williamson, Reg Waldeck, Amanda Bruno, Ekaterina Nevedomskaya, Samuel Fatoba, Niculae Constantinovici, Carl Steinbeisser, Monika Maass, Patrizia Torremante, Emmanuelle Dochy, Federica Pisa, Marc Dietrich Voss, Kishore Papineni, Jing Wang-silvanto, Robert Snijder, Xuewei Wang, Mark Lambrecht, Russ Wolfinger, Sherinne Eid, Soundarya Palanisamy, Samiul Haque, Laurent Antoni, Angela Servan, Katie Pascoe, Paul Robinson, Joana Lencart, Bertrand Jaton, Heidi Turunen, Olavi Kilkku, Pasi Pohjanjousi, Olli Voima, Liina Nevalaita, Keijo Punakivi, Sarah Seager, Shilpa Ratwani, Katarzyna Grzeslak, James Brash, Elaine Longden-Chapman, Danny Burke, Muriel Licour, Sarah Payne, Alan Yong, Flavia Lujan, Sophia Le Mare, Jan Hendrich, Michael Bussmann, Juckeland, Kotik, and Christian Reich

Subjects
Cancer survivorship, Prostate cancer, Quality of life, Patient-reported outcome measures, Diseases of the genitourinary system. Urology, RC870-923, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Cancer survivorship was recently identified as a prostate cancer (PCa) research priority by PIONEER, a European network of excellence for big data in PCa. Despite being a research priority, cancer survivorship lacks a clear and agreed definition, and there is a distinct paucity of patient-reported outcome (PRO) data available on the subject. Data collection on cancer survivorship depends on the availability and implementation of (validated) routinely collected patient-reported outcome measures (PROMs). There have been recent advances in the availability of such PROMs. For instance, the European Organisation for Research and Treatment of Cancer Quality of Life Group (EORTC QLG) is developing survivorship questionnaires. This provides an excellent first step in improving the data available on cancer survivorship. However, we propose that an agreed, standardised definition of (prostate) cancer survivorship must first be established. Only then can real-world data on survivorship be collected to strengthen our knowledge base. With more men than ever surviving PCa, this type of research is imperative to ensure that the quality of life of these men is considered as much as their quantity of life. Patient summary: As there are more prostate cancer survivors than ever before, research into cancer survivorship is crucial. We highlight the importance of such research and provide recommendations on how to carry it out. The first step should be establishing agreement on a standardised definition of survivorship. From this, patient-reported outcome measures can then be used to collect important survivorship data.

Published
2024
Full Text
View/download PDF

2. Diagnostic and prognostic factors in patients with prostate cancer: a systematic review protocol

Author

Antonella Cardone, Nicolas Mottet, Lisa Moris, Michael Lardas, Anna Haire, Francesco Barletta, Simone Scuderi, Eleni Vradi, Giorgio Gandaglia, Steven MacLennan, Bahman Farahmand, Sara J Maclennan, Zsuzsanna Devecseri, Alex Asiimwe, Laurence Collette, Anders Bjartell, James Ndow, James N'Dow, Karin Plass, Maria Ribal, Thomas Van den Broeck, Peter-Paul Willemse, Karl H Pang, Riccardo Campi, Isabella Greco, Mauro Gacci, Sergio Serni, Susan Evans-Axelsson, Ragnar Lonnerbro, Daniele Crosti, Massimiliano Meoni, Roberto Garzonio, Chris Bangma, Monique Roobol, Sebastiaan Remmers, Derya Tilki, Teemu Murtola, Tapio Visakorpi, Kirsi Talala, Teuvo Tammela, Aino Siltari, Stephane Lejeune, Femke van Diggelen, Georgia Taxiarchopoulou, Ketharini Senthilkumar, Stefanie Schütte, Sophie Byrne, Luz Fialho, Paulina Gono, Monica De Vetter, Klevisa Ceke, Bertrand De Meulder, Charles Auffray, Irina-Afrodita Balaur, Nesrine Taibi, Shaun Power, Nazanin Zounemat Kermani, Kees van Bochove, Marinel Cavelaars, Maxim Moinat, Emma Voss, Chiara Bernini, Denis Horgan, Louise Fullwood, Marc Holtorf, Doron Lancet, Gabi Bernstein, Imran Omar, Sara MacLennan, Jemma Healey, Johannes Huber, Manfred Wirth, Michael Froehner, Beate Brenner, Angelika Borkowetz, Christian Thomas, Friedemann Horn, Kristin Reiche, Markus Kreuz, Andreas Josefsson, Delila Gasi Tandefelt, Jonas Hugosson, Jack Schalken, Henkjan Huisman, Thomas Hofmarcher, Emelie Andersson, Adam Fridhammar, Frank Verholen, John-Edward Butler-Ransohoff, Todd Williamson, Kumari Chandrawansa, Dorothy Dlamini, Reg Waldeck, Megan Molnar, Amanda Bruno, Ronald Herrera, Ekaterina Nevedomskaya, Niculae Constantinovici, Carl Steinbeißer, Sini Thomas, Monika Maass, Patrizia Torremante, Marc Dietrich Voss, Guido Cuperus, Chad Dau Kishore, Papineni Jing, Wang-silvanto Steve, Hass Robert, Snijder Verena, Doyé Xuewei, Wang Andy Garnham, Mark Lambrecht, Russ Wolfinger, Stijn Rogiers, Angela Servan, Florence Lefresne, Joaquin Casariego, Mohamed Samir, Joe Lawson, Katie Pascoe, Bertrand Jaton, Daniel Bakkard, Heidi Turunen, Olavi Kilkku, Pasi Pohjanjousi, Olli Voima, Liina Nevalaita, Sonia Araujo, Elaine Longden-Chapman, Gordon McVie, Danny Burke, Paul Agapow, Sahra Derkits, Muriel Licour, Charles McCrea, Sarah Payne, Alan Yong, Flavia Lujan, Billy Franks, Michael Bussmann, and Inken Köhle

Subjects
Medicine
Abstract

Introduction As part of the PIONEER (Prostate Cancer Diagnosis and Treatment Enhancement Through the Power of Big Data in Europe) Consortium, we will explore which diagnostic and prognostic factors (DPFs) are currently being researched to previously defined clinical and patient-reported outcomes for prostate cancer (PCa).Methods and analysis This research project will follow the following four steps: (1) a broad systematic literature review of DPFs for all stages of PCa, covering evidence from 2014 onwards; (2) discussion of systematic review findings by a multidisciplinary expert panel; (3) risk of bias assessment and applicability with Prediction model Risk Of Bias Assessment Tool criteria, Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) and the Quality In Prognosis Studies tool (QUIPS) and (4) additional quantitative assessments if required.Ethics and dissemination We aim to develop an online tool to present the DPFs identified in this research and make them available across all stakeholders. There are no ethical implications.

Published
2021
Full Text
View/download PDF

3. Oral Levosimendan Increases Cerebral Blood Flow Velocities in Patients with a History of Stroke or Transient Ischemic Attack: A Pilot Safety Study

Author

Matti Kivikko, MD, PhD, Mikko Kuoppamäki, MD, PhD, Lauri Soinne, MD, PhD, Stig Sundberg, PhD, Pasi Pohjanjousi, MSc, Juha Ellmen, PhD, and Risto O. Roine, MD, PhD

Subjects
ambulatory ECG, cerebral blood flow, levosimendan, stroke, TIA, Therapeutics. Pharmacology, RM1-950
Abstract

Background: Intravenous levosimendan is indicated for acute heart failure. The compound has shown promising beneficial effects in ischemic stroke models. Objective: We evaluated the efficacy and safety of oral levosimendan in patients with a history of cerebral ischemia. Methods: In a randomized, double-blind, placebo-controlled, parallel-group study, 16 patients with a history of ischemic stroke/transient ischemic attack received oral levosimendan in 5 escalating doses from 0.125 to 2.0 mg daily for 18-day intervals of each dose; 5 patients received placebo. Twenty-four-hour ambulatory ECG and cerebral blood flow velocities using transcranial Doppler ultrasound were recorded at baseline and at the end of each dosing period. Vasomotor reactivity was assessed via the breath holding index. In addition, plasma levels of N-terminal-pro-B-type natriuretic peptide (NT-pro-BNP) and the metabolites of levosimendan were determined. Results: Levosimendan induced an increase in cerebral blood flow velocities and a decrease in NT-pro-BNP compared with placebo. There was no significant effect on breath holding index. Doses ≥0.5 mg increased heart rate by 5 to 9 beats/min. The dose level of 2.0 mg exceeded the preset safety margin of ventricular extrasystoles per hour (ie, upper 90% CI of the ratio of levosimendan to placebo above 2) with an estimate of 3.10 (90% CI, 0.95–10.07). Conclusions: Oral levosimendan increases cerebral blood flow velocities and diminishes NT-pro-BNP levels in patients with earlier ischemic cerebrovascular event. Daily doses up to 1.0 mg were well tolerated, whereas the 2.0 mg dose level induced an increase in ventricular extrasystoles. ClinicalTrials.gov identifier: NCT00698763.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results